Glaucoma laser treatment ready to go to trial

Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.

The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.

IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.